Literature DB >> 17877932

Indications for implantable cardioverter defibrillator use for primary prevention of sudden cardiac death.

Mithilesh K Das1, Rajdeep Gaitonde, John M Miller.   

Abstract

The implantable cardioverter defibrillator (ICD) is used for primary and secondary prophylaxis of sudden cardiac death in high-risk patients. Although several trials have demonstrated the superiority of ICD over standard medical therapy or antiarrhythmic medication in this population, a few trials have not shown survival benefit. This review examines the major ICD trials that provide the basis for current therapy in this rapidly changing and very important area of cardiology.

Entities:  

Mesh:

Year:  2007        PMID: 17877932     DOI: 10.1007/bf02938364

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  42 in total

Review 1.  Implantable cardioverter-defibrillator therapy in clinical practice.

Authors:  David A Cesario; G William Dec
Journal:  J Am Coll Cardiol       Date:  2006-03-27       Impact factor: 24.094

Review 2.  Frequency of sudden cardiac death and profiles of risk.

Authors:  R J Myerburg; A Interian; R M Mitrani; K M Kessler; A Castellanos
Journal:  Am J Cardiol       Date:  1997-09-11       Impact factor: 2.778

3.  Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings.

Authors:  M Mirowski; P R Reid; M M Mower; L Watkins; V L Gott; J F Schauble; A Langer; M S Heilman; S A Kolenik; R E Fischell; M L Weisfeldt
Journal:  N Engl J Med       Date:  1980-08-07       Impact factor: 91.245

4.  Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators.

Authors:  Alan Kadish; Andi Schaechter; Haris Subacius; Emil Thattassery; William Sanders; Kelley P Anderson; Alan Dyer; Jeffrey Goldberger; Joseph Levine
Journal:  J Am Coll Cardiol       Date:  2006-05-30       Impact factor: 24.094

5.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

Review 6.  Epidemiology and stratification of risk for sudden cardiac death.

Authors:  Philip J Podrid; Robert J Myerburg
Journal:  Clin Cardiol       Date:  2005-11       Impact factor: 2.882

7.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

8.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT.

Authors:  S Adam Strickberger; John D Hummel; Thomas G Bartlett; Howard I Frumin; Claudio D Schuger; Scott L Beau; Cynthia Bitar; Fred Morady
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

9.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

10.  Natural history of Brugada syndrome: insights for risk stratification and management.

Authors:  Silvia G Priori; Carlo Napolitano; Maurizio Gasparini; Carlo Pappone; Paolo Della Bella; Umberto Giordano; Raffaella Bloise; Carla Giustetto; Roberto De Nardis; Massimiliano Grillo; Elena Ronchetti; Giovanna Faggiano; Janni Nastoli
Journal:  Circulation       Date:  2002-03-19       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.